A Study Comparing Two Forms of Didanosine in HIV-infected Patients
Status:
Completed
Trial end date:
1999-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the coated-capsule form of didanosine (ddI) is as safe
and absorbed by the body as well as the chewable-tablet form of ddI.
Didanosine (ddI) is an anti-HIV drug. The effectiveness of ddI can be lowered by acid in the
stomach. To prevent this, patients take antacids with ddI. The coated-capsule form of ddI may
replace the need for antacids.